An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study-Reference-Cited by-同舟云学术

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Published:2019-04 Issue:4 Volume:6 Page:e194-e203
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Savona Michael R,Odenike Olatoyosi,Amrein Philip C,Steensma David P,DeZern Amy E,Michaelis Laura C,Faderl Stefan,Harb Wael,Kantarjian Hagop,Lowder James,Oganesian Aram,Azab Mohammad,Garcia-Manero Guillermo

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

3. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

4. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial;Steensma;J Clin Oncol,2009

5. 5-aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal;Ghoshal;Mol Cell Biol,2005

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting transposable elements in cancer: developments and opportunities;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

3. Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance;Nature Cancer;2024-06-06

4. Unzippable Siamese Nanoparticles for Programmed Two‐Stage Cancer Immunotherapy;Advanced Materials;2024-06-02

5. Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance;2024-05-21